Nontuberculous Mycobacterial Lung Disease: Real-World Application of New Guidelines and Treatment Advances

To participate in this activity, please:

Nontuberculosis mycobacterial lung disease (NTM-LD) is a frequently fatal lung disease that is now more common than tuberculosis in the United States. Treatment is generally very challenging due to lack of medications approved for first-line therapy, adverse events, drug-drug interactions, need for long-term dual and triple combination therapy, among other issues. In the first of this 2-part activity, Drs. Shannon Kasperbauer and Kevin Winthrop discuss the recommendations in the 2020 ATS/ERS/ESCMID/IDSA guidelines, for which Dr. Winthrop was a senior author, and the evidence supporting the recommendations. Extensive discussion focuses on the macrolides and aminoglycosides, including treatment advances. The second part includes case studies to illustrate how to individualize the guideline recommendations so that treatment is initiated and optimized to best meet the needs and characteristics of the individual patient. Throughout the activity, the faculty share their experiences and provide pearls and pitfalls in overcoming the challenges in managing patients with NTM-LD, such as taking medications with ice cream in the evening to improve adherence and promote weight gain. Join the highly experienced faculty as they help in the real-world application of the new guidelines and treatment advances.

Course Credit:

2.00 AMA PRA Category 1 CreditsTM


Opens: 2021-05-21
Closes: 2022-05-21

Target Audience:

This activity is intended for pulmonologists, infectious disease specialists, and other healthcare professionals who care for patients with lung diseases.

This activity is supported by an independent educational grant from Insmed.

    Presenting Faculty

  • Shannon H. Kasperbauer, MD

    Associate Professor of Medicine
    Division of Mycobacterial and Respiratory Infections
    National Jewish Health
    Associate Professor of Medicine, Infectious Diseases
    University of Colorado, School of Medicine
    Denver, Colorado

  • Kevin Winthrop, MD, MPH

    Professor of Public Health, Infectious Diseases, Ophthalmology
    Oregon Health & Science University
    Portland, Oregon

Learning Objectives

  • Describe key treatment concepts as described in the 2020 clinical practice guideline on nontuberculous mycobacterial lung disease (NTM-LD) jointly sponsored by American Thoracic Society, European Respiratory Society, European Society of Clinical Microbiology and Infectious Diseases, and Infectious Diseases Society of America
  • Summarize the clinical impact of the latest clinical data and therapeutic advances in NTM-LD
  • Develop patient-centered treatment strategies for NTM-LD that align with the latest evidence-based guideline recommendations and therapeutic advances
  • Collaborate with patients to better individualize treatment over the course of the disease

Faculty Disclosures

Shannon H. Kasperbauer, MD

Consultant: AN2 Therapeutics, Insmed, NTMir, Paratek

Kevin Winthrop, MD, MPH

Consultant: Insmed, Paratek, Red Hill Biopharma, Horizon, Spero

Research Support: Insmed

Accreditation and Certification

The Annenberg Center for Health Sciences at Eisenhower is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 2.00 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Eugene Cullen, MD (Peer Reviewer)
No significant relationships to disclose.

Gregory Scott, PharmD, RPh (Medical Writer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant commercial relationships to disclose.